TY - JOUR
T1 - Imaging outcome measures of neuroprotection and repair in MS
T2 - A consensus statement from NAIMS
AU - Oh, Jiwon
AU - Ontaneda, Daniel
AU - Azevedo, Christina
AU - Klawiter, Eric C.
AU - Absinta, Martina
AU - Arnold, Douglas L.
AU - Bakshi, Rohit
AU - Calabresi, Peter A.
AU - Crainiceanu, Ciprian
AU - Dewey, Blake
AU - Freeman, Leorah
AU - Gauthier, Susan
AU - Henry, Roland
AU - Inglese, Mathilde
AU - Kolind, Shannon
AU - Li, David K.B.
AU - Mainero, Caterina
AU - Menon, Ravi S.
AU - Nair, Govind
AU - Narayanan, Sridar
AU - Nelson, Flavia
AU - Pelletier, Daniel
AU - Rauscher, Alexander
AU - Rooney, William
AU - Sati, Pascal
AU - Schwartz, Daniel
AU - Shinohara, Russell T.
AU - Tagge, Ian
AU - Traboulsee, Anthony
AU - Wang, Yi
AU - Yoo, Youngjin
AU - Yousry, Tarek
AU - Zhang, Yunyan
AU - Sicotte, Nancy L.
AU - Reich, Daniel S.
N1 - Publisher Copyright:
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2019/3/12
Y1 - 2019/3/12
N2 - To summarize current and emerging imaging techniques that can be used to assess neuroprotection and repair in multiple sclerosis (MS), and to provide a consensus opinion on the potential utility of each technique in clinical trial settings.MethodsClinicians and scientists with expertise in the use of MRI in MS convened in Toronto, Canada, in November 2016 at a North American Imaging in Multiple Sclerosis (NAIMS) Cooperative workshop meeting. The discussion was compiled into a manuscript and circulated to all NAIMS members in attendance. Edits and feedback were incorporated until all authors were in agreement.ResultsA wide spectrum of imaging techniques and analysis methods in the context of specific study designs were discussed, with a focus on the utility and limitations of applying each technique to assess neuroprotection and repair. Techniques were discussed under specific themes, and included conventional imaging, magnetization transfer ratio, diffusion tensor imaging, susceptibility-weighted imaging, imaging cortical lesions, magnetic resonance spectroscopy, PET, advanced diffusion imaging, sodium imaging, multimodal techniques, imaging of special regions, statistical considerations, and study design.ConclusionsImaging biomarkers of neuroprotection and repair are an unmet need in MS. There are a number of promising techniques with different strengths and limitations, and selection of a specific technique will depend on a number of factors, notably the question the trial seeks to answer. Ongoing collaborative efforts will enable further refinement and improved methods to image the effect of novel therapeutic agents that exert benefit in MS predominately through neuroprotective and reparative mechanisms.
AB - To summarize current and emerging imaging techniques that can be used to assess neuroprotection and repair in multiple sclerosis (MS), and to provide a consensus opinion on the potential utility of each technique in clinical trial settings.MethodsClinicians and scientists with expertise in the use of MRI in MS convened in Toronto, Canada, in November 2016 at a North American Imaging in Multiple Sclerosis (NAIMS) Cooperative workshop meeting. The discussion was compiled into a manuscript and circulated to all NAIMS members in attendance. Edits and feedback were incorporated until all authors were in agreement.ResultsA wide spectrum of imaging techniques and analysis methods in the context of specific study designs were discussed, with a focus on the utility and limitations of applying each technique to assess neuroprotection and repair. Techniques were discussed under specific themes, and included conventional imaging, magnetization transfer ratio, diffusion tensor imaging, susceptibility-weighted imaging, imaging cortical lesions, magnetic resonance spectroscopy, PET, advanced diffusion imaging, sodium imaging, multimodal techniques, imaging of special regions, statistical considerations, and study design.ConclusionsImaging biomarkers of neuroprotection and repair are an unmet need in MS. There are a number of promising techniques with different strengths and limitations, and selection of a specific technique will depend on a number of factors, notably the question the trial seeks to answer. Ongoing collaborative efforts will enable further refinement and improved methods to image the effect of novel therapeutic agents that exert benefit in MS predominately through neuroprotective and reparative mechanisms.
UR - http://www.scopus.com/inward/record.url?scp=85062886285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062886285&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000007099
DO - 10.1212/WNL.0000000000007099
M3 - Review article
C2 - 30787160
AN - SCOPUS:85062886285
SN - 0028-3878
VL - 92
SP - 519
EP - 533
JO - Neurology
JF - Neurology
IS - 11
ER -